Coexistence of P53 and KRAS mutations enhances ERK1/2 signaling by inducing EGR1 expression through mutp53 and c-JUN interaction

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling Pathways

Background:

• The ERK1/2 pathway is frequently dysregulated in cancer, often due to mutations in RAS, BRAF, or ERBB2 (HER2) amplifications.
• Co-occurrence of ERK1/2 hyperactivation and TP53 mutations is common in various cancers, leading to worse clinical outcomes.
• The precise mechanisms linking ERK1/2 signaling and mutant p53 in cancer progression are not well understood.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying the cooperation between ERK1/2 signaling and mutant p53.
• To investigate how oncogenic KRAS mutations influence the interaction between c-JUN and mutant p53.
• To identify key transcriptional regulators involved in KRAS-mutant p53 driven metastasis.

Main Methods:

• Investigated the role of oncogenic KRAS in activating c-JUN.
• Examined the physical interaction between c-JUN and mutant p53.
• Analyzed the upregulation of pro-metastatic transcriptional networks, including EGR1.
• Assessed the impact of these interactions on cancer cell metastatic traits.

Main Results:

• Oncogenic KRAS activates c-JUN, which physically interacts with mutant p53.
• This interaction leads to the hyperactivation of pro-metastatic transcriptional networks.
• Mutant p53 and c-JUN collaboratively upregulate EGR1, a critical driver of tumor invasion and metastasis.
• Combined signaling pathways significantly enhance pro-metastatic phenotypes in cancer cells.

Conclusions:

• The study reveals a direct mechanism for KRAS-mutant p53 cooperation in promoting cancer metastasis via c-JUN and EGR1.
• Findings provide insights into the frequent co-occurrence of KRAS and p53 mutations in cancer.
• Identified a novel therapeutic targetable interaction for cancers harboring these mutations.